Treatment of new-onset ulcerative colitis and ulcerative proctitis: A retrospective study

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 3, 2012, Pages 248-256

  Richter, J M ^a   Kushkuley, S ^b   Barrett, J A ^c   Oster, G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b POLICY ANALYSIS INC PAI   (United States)

^c Aptalis Pharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; BIOLOGICAL PRODUCT; BUDESONIDE; CYCLOSPORIN A; HYDROCORTISONE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; OLSALAZINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROCTITIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SIGMOIDOSCOPY; SUPPOSITORY; ULCERATIVE COLITIS; ULCERATIVE PROCTITIS; UNITED STATES;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROCTITIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUPPOSITORIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863315321     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05175.x     Document Type: Article

References (23)

1. Bernstein CN, Blanchard JF, Rawsthorne P, et al,. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999; 149: 916-24. (Pubitemid 29230706)
2. Cohen RD, Woseth DM, Thisted RA, et al,. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263-76. (Pubitemid 30263523)
3. Bello C, Belaiche J, Louis E, et al,. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalamine after a course of corticosteroids. J Crohns Colitis 2011; 5: 196-202.
4. Meucci G, Vecchi M, Astegiano M, et al,. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di studio per le malattie infiammatorie intestinali (GSMII). Am J Gastroenterol 2000; 95: 469-73.
5. Kornbluth A, Sachar DB, and Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
6. Hanauer SB, Sparrow M,. Therapy of ulcerative colitis. Curr Opin Gastroenterol 2004; 20: 345-50. (Pubitemid 38813676)
7. Regueiro M, Loftus EV, Steinhart AH, et al,. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis 2006; 12: 972-8. (Pubitemid 44498286)
8. Karagozian R, Burakoff R,. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag 2007; 3: 893-903. (Pubitemid 350162088)
9. Langan RC, Gotsch PB, Krafczyk MA, et al,. Ulcerative colitis: diagnosis and treatment. Am Fam Physician 2007; 76: 1323-30.
10. Tremaine WJ, Sandborn WJ, Loftus EV, et al,. A prospective cohort study of practice guidelines in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2401-6. (Pubitemid 32769202)
11. Health Insurance Portability and Accountability Act of 1996, 1320-d2.
12. Public Welfare - Protection of Human Subjects, 45 CFR, 46.101.
13. Thirumurthi S, Chowdhury R, Richardson P, et al,. Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans. Dig Dis Sci 2010; 55: 2592-8.
14. Munkholm P, Michetti P, Probert CS, et al,. Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine. Eur J Gastroenterol Hepatol 2010; 22: 912-6.
15. Harris MS, Lichtenstein GR,. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 996-1009.
16. Kane SV, Cohen RD, Aikens JE, et al,. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33. (Pubitemid 32959535)
17. Pica R, Paoluzi OA, Iacopini F, et al,. Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis 2004; 10: 731-6. (Pubitemid 39545217)
18. Siriwardana A, Koo J, Ng W, et al,. Azathioprine, 6-mercaptopurine and thiopurine in inflammatory bowel disease: what is the current clinical practice? J Gastroenterol Hepatol 2009; 24: A311-2.
19. Reddy SI, Friedman S, Telford JJ, et al,. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 2005; 100: 1357-61. (Pubitemid 40904362)
20. Spiegel BM, Ho W, Esrailian E, et al,. Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists. Clin Gastroenterol Hepatol 2009; 7: 168-74.
21. Langholz E,. Review: current trends in inflammatory bowel disease: the natural history. Therap Adv Gastroenterol 2010; 3: 77-86.
22. Herrinton LJ, Liu L, Fireman B, et al,. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009; 137: 502-11.
23. Odes S, Vardi H, Friger M, et al,. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006; 131: 719-28. (Pubitemid 44307060)